Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma
European Journal of Cancer, Volume 48, No. 16, Year 2012
Notification
URL copied to clipboard!
Description
Background: There is currently no early predictive marker of survival for patients receiving chemotherapy for malignant pleural mesothelioma (MPM). Tumour response may be predictive for overall survival (OS), though this has not been explored. We have thus undertaken a combined-analysis of OS, from a 42 day landmark, of 526 patients receiving systemic therapy for MPM. We also validate published progression-free survival rates (PFSRs) and a progression-free survival (PFS) prognostic-index model. Methods: Analyses included nine MPM clinical trials incorporating six European Organisation for Research and Treatment of Cancer (EORTC) studies. Analysis of OS from landmark (from day 42 post-treatment) was considered regarding tumour response. PFSR analysis data included six non-EORTC MPM clinical trials. Prognostic index validation was performed on one non-EORTC data-set, with available survival data. Results: Median OS, from landmark, of patients with partial response (PR) was 12·8 months, stable disease (SD), 9·4 months and progressive disease (PD), 3·4 months. Both PR and SD were associated with longer OS from landmark compared with disease progression (both p < 0·0001). PFSRs for platinum-based combination therapies were consistent with published significant clinical activity ranges. Effective separation between PFS and OS curves provided a validation of the EORTC prognostic model, based on histology, stage and performance status. Conclusion: Response to chemotherapy is associated with significantly longer OS from landmark in patients with MPM. © 2012 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Blayney, Jaine K.
United Kingdom, Belfast
Queen's University Belfast
Ceresoli, Giovanni Luca
Italy, Bergamo
Humanitas Gavazzeni Hospital
Castagneto, Bruno
Italy
San Giacamo Hospital
O'Brien, Mary E.R.
United Kingdom, Sutton
Royal Marsden Hospital
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Hasan, Baktiar
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Sylvester, Richard J.
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Rudd, Robin
United Kingdom, London
London Lung Cancer Group
Steele, Jeremy
United Kingdom, London
St Bartholomew's Hospital
Busacca, Sara
United Kingdom, Leicester
University of Leicester
Porta, Camillo G.
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Mutti, Luciano
Italy, Vercelli
Vercelli National Health Trust
O'Byrne, K. J.
Ireland, Dublin
St James's Hospital
Scullin, Paula
United Kingdom, Belfast
Northern Ireland Cancer Centre
Gaafar, Rabab Mohamed
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Egypt, Giza
Cairo University
Baas, Paul
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Netherlands, Amsterdam
The Netherlands Cancer Institute
van Meerbeeck, J. P.A.M.
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Belgium, Ghent
Universitair Ziekenhuis Gent
Fennell, Dean Andrew
United Kingdom, Leicester
University of Leicester
Statistics
Citations: 17
Authors: 17
Affiliations: 15
Identifiers
Doi:
10.1016/j.ejca.2012.05.018
ISSN:
09598049
e-ISSN:
18790852
Research Areas
Cancer
Health System And Policy